• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ruxolitinib withdrawal syndrome leading to tumor lysis.

作者信息

Dai Tong, Friedman Ellen W, Barta Stefan K

机构信息

Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY.

出版信息

J Clin Oncol. 2013 Oct 10;31(29):e430-2. doi: 10.1200/JCO.2012.47.6473. Epub 2013 Jun 10.

DOI:10.1200/JCO.2012.47.6473
PMID:23752116
Abstract
摘要

相似文献

1
Ruxolitinib withdrawal syndrome leading to tumor lysis.导致肿瘤溶解的鲁索替尼撤药综合征。
J Clin Oncol. 2013 Oct 10;31(29):e430-2. doi: 10.1200/JCO.2012.47.6473. Epub 2013 Jun 10.
2
Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.芦可替尼对一名JAK2阴性慢性粒单核细胞白血病-2型患者的疾病修饰活性。
Leuk Lymphoma. 2017 May;58(5):1271-1272. doi: 10.1080/10428194.2016.1225209. Epub 2016 Sep 23.
3
A life-threatening ruxolitinib discontinuation syndrome.一种危及生命的鲁索替尼停药综合征。
Am J Hematol. 2017 Aug;92(8):833-838. doi: 10.1002/ajh.24775. Epub 2017 Jun 1.
4
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.一项关于Janus激酶（JAK）1和2抑制剂鲁索替尼用于复发或难治性急性髓系白血病患者的I/II期研究。
Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):171-6. doi: 10.1016/j.clml.2014.08.003. Epub 2014 Sep 17.
5
Infections associated with ruxolitinib: study in the French Pharmacovigilance database.与鲁索替尼相关的感染：法国药物警戒数据库研究
Ann Hematol. 2018 May;97(5):913-914. doi: 10.1007/s00277-018-3242-8. Epub 2018 Jan 16.
6
Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.芦可替尼治疗原发性骨髓纤维化所致持续性足部溃疡
J Oncol Pharm Pract. 2018 Apr;24(3):226-228. doi: 10.1177/1078155217697488. Epub 2017 Mar 10.
7
Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.Janus激酶1/2抑制剂芦可替尼治疗3例与TMEM173激活突变相关的血管病变患儿的疗效
J Allergy Clin Immunol. 2016 Dec;138(6):1752-1755. doi: 10.1016/j.jaci.2016.07.015. Epub 2016 Aug 20.
8
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.伊布替尼相关的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤及套细胞淋巴瘤肿瘤溶解综合征：病例系列及文献综述
J Oncol Pharm Pract. 2018 Oct;24(7):544-549. doi: 10.1177/1078155217718617. Epub 2017 Jul 16.
9
Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.鲁索替尼治疗真性红细胞增多症后骨髓纤维化患者后发生肿瘤溶解综合征
Intern Med. 2017 Sep 1;56(17):2335-2338. doi: 10.2169/internalmedicine.8706-16. Epub 2017 Aug 10.
10
Janus activated kinase inhibition in myelofibrosis.骨髓纤维化中 Janus 激酶抑制作用
Indian J Cancer. 2012 Jul-Sep;49(3):260-5. doi: 10.4103/0019-509X.104482.

引用本文的文献

1
Rapid Hepatomegaly From Ruxolitinib Discontinuation Syndrome.芦可替尼停药综合征导致的快速肝肿大
HCA Healthc J Med. 2023 Apr 28;4(2):199-204. doi: 10.36518/2689-0216.1518. eCollection 2023.
2
Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups.SFGM-TC 和 FIM 专家组关于骨髓纤维化患者在异基因造血移植前使用芦可替尼的建议
Bone Marrow Transplant. 2021 Aug;56(8):1888-1899. doi: 10.1038/s41409-021-01252-7. Epub 2021 Mar 25.
3
Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.
芦可替尼治疗骨髓纤维化的持续性：生物学和临床意义。
Haematologica. 2021 May 1;106(5):1244-1253. doi: 10.3324/haematol.2020.262691.
4
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.芦可替尼停药综合征：251例骨髓纤维化患者的发生率、危险因素及管理
Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1.
5
Management of myelofibrosis after ruxolitinib failure.芦可替尼治疗失败后的骨髓纤维化的管理。
Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20.
6
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.在常规临床实践中治疗的慢性淋巴细胞白血病患者停止伊布替尼治疗后疾病迅速进展。
Leuk Lymphoma. 2019 Nov;60(11):2712-2719. doi: 10.1080/10428194.2019.1602268. Epub 2019 Apr 24.
7
Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.JAK 激活环磷酸化的积累与骨髓纤维化中 I 型 JAK 抑制剂撤药综合征有关。
Sci Adv. 2018 Nov 28;4(11):eaat3834. doi: 10.1126/sciadv.aat3834. eCollection 2018 Nov.
8
Acute respiratory distress syndrome; A rare complication caused by usage of ruxolitinib.急性呼吸窘迫综合征；一种由芦可替尼使用引起的罕见并发症。
Respir Med Case Rep. 2017 Sep 18;22:243-245. doi: 10.1016/j.rmcr.2017.09.003. eCollection 2017.
9
Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.鲁索替尼治疗真性红细胞增多症后骨髓纤维化患者后发生肿瘤溶解综合征
Intern Med. 2017 Sep 1;56(17):2335-2338. doi: 10.2169/internalmedicine.8706-16. Epub 2017 Aug 10.
10
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.曾接受过Janus激酶1/2抑制剂治疗的骨髓纤维化患者接受异基因造血细胞移植的结果
Biol Blood Marrow Transplant. 2016 Mar;22(3):432-40. doi: 10.1016/j.bbmt.2015.10.005. Epub 2015 Oct 19.